FierceBiotech

Dezima Pharma raises €14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001

Naarden, The Netherlands, 28 February 2013 – Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that is has raised a total of ...
FierceBiotech

Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia

NAARDEN, Netherlands--(BUSINESS WIRE)--Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that it has received very positive ...
PE Hub

Amgen to acquire Forbion-backed Dezima for up to $1.55 bln

Naarden, The Netherlands, 16 September 2015 – Forbion Capital Partners (“Forbion”), one of the leading Dutch venture capital firms investing in world-class healthcare technologies, announces that its ...
Business Wire

Amgen acquires Forbion portfolio company Dezima Pharma

NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners (“Forbion”), one of the leading Dutch venture capital firms investing in world-class healthcare technologies, announces that its ...
Business Wire

Dezima Pharma’s CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet

NAARDEN, The Netherlands--(BUSINESS WIRE)--Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, today announced the publication of the phase 2b ...
PR Newswire

Ischemic Heart Disease (IHD) Drugs Market Worth USD 8.46 Billion to 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

JERSEY CITY, N.J., May 30, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Ischemic Heart Disease (IHD) Drugs Market- (By Disease ...